Investigational Drug Information for CC-220
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug CC-220?
CC-220 is an investigational drug.
There have been 22 clinical trials for CC-220.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 12th 2021.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Lymphoma. The leading clinical trial sponsors are Celgene, Celgene Corporation, and Bristol-Myers Squibb.
There are twenty-nine US patents protecting this investigational drug and two hundred and sixty-six international patents.
Summary for CC-220
US Patents | 29 |
International Patents | 266 |
US Patent Applications | 127 |
WIPO Patent Applications | 75 |
Japanese Patent Applications | 21 |
Clinical Trial Progress | Phase 2 (2021-11-12) |
Vendors | 24 |
Recent Clinical Trials for CC-220
Title | Sponsor | Phase |
---|---|---|
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | Mayo Clinic | Phase 1/Phase 2 |
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | Bristol-Myers Squibb | Phase 1/Phase 2 |
Clinical Trial Summary for CC-220
Top disease conditions for CC-220
Top clinical trial sponsors for CC-220
US Patents for CC-220
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
CC-220 | See Plans and Pricing | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | Celgene Corporation (Summit, NJ) | See Plans and Pricing |
CC-220 | See Plans and Pricing | Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione | Celgene Corporation (Summit, NJ) | See Plans and Pricing |
CC-220 | See Plans and Pricing | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast | Celgene Corporation (Summit, NJ) | See Plans and Pricing |
CC-220 | See Plans and Pricing | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | Celgene Corporation (Summit, NJ) | See Plans and Pricing |
CC-220 | See Plans and Pricing | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-- dione for the treatment of systemic lupus erythematosus | Celgene Corporation (Summit, NJ) | See Plans and Pricing |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CC-220
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
CC-220 | Australia | AU2015305449 | 2034-08-22 | See Plans and Pricing |
CC-220 | Australia | AU2021209158 | 2034-08-22 | See Plans and Pricing |
CC-220 | Brazil | BR112017003620 | 2034-08-22 | See Plans and Pricing |
CC-220 | Canada | CA2958867 | 2034-08-22 | See Plans and Pricing |
CC-220 | Chile | CL2017000416 | 2034-08-22 | See Plans and Pricing |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |